---
title: "TD Cowen Remains a Buy on Evotec AG (EVO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285510191.md"
description: "TD Cowen analyst Brendan Smith has maintained a Buy rating on Evotec AG (EVO) with a price target of $4.00, while the stock closed at $3.24. The analyst has an average return of 3.2% and a 38.76% success rate. Evotec AG has a consensus rating of Moderate Buy, with a price target consensus of $4.67, indicating a potential upside of 44.14%. H.C. Wainwright also reiterated a Buy rating with a $7.00 price target in a previous report."
datetime: "2026-05-07T08:05:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285510191.md)
  - [en](https://longbridge.com/en/news/285510191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285510191.md)
---

# TD Cowen Remains a Buy on Evotec AG (EVO)

In a report released yesterday, Brendan Smith from TD Cowen maintained a Buy rating on Evotec AG, with a price target of $4.00. The company’s shares closed yesterday at $3.24.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Smith covers the Healthcare sector, focusing on stocks such as Schrodinger, 908 Devices, and Alpha Teknova. According to TipRanks, Smith has an average return of 3.2% and a 38.76% success rate on recommended stocks.

Evotec AG has an analyst consensus of Moderate Buy, with a price target consensus of $4.67, which is a 44.14% upside from current levels. In a report released on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

### Related Stocks

- [EVO.US](https://longbridge.com/en/quote/EVO.US.md)
- [EVT.DE](https://longbridge.com/en/quote/EVT.DE.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [SDGR.US](https://longbridge.com/en/quote/SDGR.US.md)
- [MASS.US](https://longbridge.com/en/quote/MASS.US.md)
- [TKNO.US](https://longbridge.com/en/quote/TKNO.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)